Bruce A. Sullenger

Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts.

ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN.

GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.

Bowdoin College is an independent, nonsectarian, coeducational residential, undergraduate liberal arts institution founded in 1794. It is located in Brunswick, ME.

Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC.

Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom.

Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts.

Synthesis Capital is a venture capital firm founded in 2007. The firm is headquartered in Boston, Massachusetts.

Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC.

Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.

Arthrosi Therapeutics, Inc. engages in the development of biotechnology treatment. The company was founded in 2017 and is headquartered in Laguna Hills, CA.

Spectral MD, Inc. engages in the manufacture of medical devices. It focuses on the modernization of wound care offering DeepView a wound imaging system. The company was founded by J. Michael DiMaio and is headquartered in Dallas, TX.

Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA.

Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.

Amberstone Biosciences, Inc. is a company that aims to eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. The company is based in Laguna Hills, CA. The company's team of scientists and engineers strives to discover and develop transformative immunotherapeutics, pioneering a new wave of therapeutic breakthroughs. The company is developing first-in-class tumor microenvironment activated therapeutic (T-MATE). The company was founded in 2018 by Guikai George Wu. Guikai George Wu has been the CEO since 2018.

AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018.